Gene Expression of CD70 and CD27 Is Increased in Alopecia Areata Lesions and Associated with Disease Severity and Activity

Table 2

Clinical data of patients with AA (n = 44).

Clinical data	No.	%
Duration of AA lesions (months)
<3 months	8	20.0
3–12 months	11	27.5
12–24 months	5	12.5
2–5 years	9	22.5
≥5 years	7	17.5
Min.–Max.	0.25–168.0
Mean ± SD	26.98 ± 39.75
Median (IQR)	12.0 (3.0–36.0)
Course
Progressive	27	67.5
Fluctuating	5	12.5
Stationary	8	20.0
Age of disease onset (years)
Children (0- <13)	6	15.0
Adolescents and young youth (13- <25)	16	40.0
Adulthood (25- <40)	10	25.0
Middle age (40- <60)	8	20.0
Min.–Max.	2.0–50.0
Mean ± SD	25.58 ± 13.25
Median (IQR)	24.0 (17.0–32.0)
Alopecia in other sites (beard or eyebrows)	14	35.0
SALT score
S1 (<25% hair loss)	22	55.0
S2 (25–49% hair loss)	9	22.5
S3 (50–74% hair loss)	7	17.5
S4 (75–99% hair loss)	0	0.0
S5 (100% hair loss)	2	5.0
Min.–Max.	1.50–100.0
Mean ± SD	25.08 ± 26.02
Median (IQR)	12.0 (3.0–42.0)
Pattern
Patchy	22	55.0
Single patch	7	17.5
Multiple separate patches	12	30.0
Multiple reticular patches	3	7.5
Ophiasis ± other patterns	16	40.0
Ophiasis	8	20.0
Multiple separate patches and ophiasis	7	17.5
Ophiasis and sisaipho	1	2.5
Universalis	2	5.0
Previous attacks of AA	22	55.0
Family history of AA	3	7.5
Family history of atopy	5	12.5
Family history of autoimmune disorders	3	7.5
Nail changes (pitting, ridging, dystrophy)	7	17.5
Black dots	30	75.0
Broken hairs	16	40.0
Tapering hairs	26	65.0
Positive hair pull test	22	55.0

SD: standard deviation; IQR: interquartile range. AA: alopecia areata; SALT : Severity of Alopecia Tool.